Dan Emil Lind | Ruth Palmer Labhttps://deploy-preview-3--ruthpalmerlab.netlify.app/author/dan-emil-lind/Dan Emil LindHugo Blox Builder (https://hugoblox.com)en-ushttps://deploy-preview-3--ruthpalmerlab.netlify.app/author/dan-emil-lind/avatar_hu28d556cf968c0a5fa6e87ec326edbe81_22777_270x270_fill_q75_lanczos_center.jpgDan Emil Lindhttps://deploy-preview-3--ruthpalmerlab.netlify.app/author/dan-emil-lind/Spatial transcriptomics exploration of the primary neuroblastoma microenvironment in archived FFPE samples unveils novel paracrine interactionshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/spatial_transcriptomics_neuroblastoma/Wed, 01 Oct 2025 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/spatial_transcriptomics_neuroblastoma/Anaplastic Lymphoma Kinase signaling stabilizes SLC3A2 expression via MARCH11 to promote neuroblastoma cell growthhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/slc3a2/Mon, 10 Jun 2024 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/slc3a2/Comparison of (177)Lu-octreotate and (177)Lu-octreotide for treatment in human neuroblastoma-bearing micehttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/lu_octreotide_comparison/Thu, 30 May 2024 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/lu_octreotide_comparison/ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibitionhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/atri2/Tue, 02 Jan 2024 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/atri2/ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expressionhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkfusion_serpin/Tue, 21 Feb 2023 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkfusion_serpin/ATR inhibition enables complete tumour regression in ALK-driven NB mouse modelshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/atri1/Wed, 24 Nov 2021 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/atri1/ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutationhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkal2_mycn/Mon, 01 Feb 2021 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkal2_mycn/11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastomahttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/dlg2_neuroblastoma/Tue, 22 Sep 2020 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/dlg2_neuroblastoma/Repotrectinib (TPX-0005) effectively reduces growth of ALK-driven neuroblastoma cellshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/repotrectinib/Wed, 18 Dec 2019 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/repotrectinib/Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cellshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alectinib_neuroblastoma/Tue, 01 Jan 2019 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alectinib_neuroblastoma/